Search Results - "Bueno, Teresa Moran"

PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis by Majem, Margarita, Cobo, Manuel, Isla, Dolores, Marquez-Medina, Diego, Rodriguez-Abreu, Delvys, Casal-Rubio, Joaquín, Bueno, Teresa Moran, Bernabé-Caro, Reyes, Parente, Diego Pérez, Ruiz-Gracia, Pedro, Arroyo, Marta Marina, Paz-Ares, Luis

“…Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond to immunotherapy and as a…”
Get full text

PD-(L)1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer patients with high PD-L1 expression: A network meta-analysis by Majem, Margarita, Cobo, Manuel, Isla, Dolores, Marquez-Medina, Diego, Rodriguez-Abreu, Delvys, Casal Rubio, Joaquín, Moran Bueno, Teresa, Bernabe Caro, Reyes, Perez Parente, Diego, Ruiz Gracia, Pedro, Marina Arroyo, Marta, Paz-Ares, Luis G.

“…Abstract only 9076 Background: PD-L1 has emerged as a potential biomarker for predicting responses to immunotherapy and as a prognostic factor in non-small…”
Get full text

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial by Paz-Ares, Luis, Dvorkin, Mikhail, Chen, Yuanbin, Reinmuth, Niels, Hotta, Katsuyuki, Hochmair, Maximilian J, Özgüroğlu, Mustafa, Ji, Jun Ho, Bondarenko, Igor, Byrne, Natalie, Shire, Norah, Goldman, Jonathan W, Batagelj, Emilio, Casarini, Ignacio, Pastor, Anea Viviana, Hartl, Sylvia, Hochmair, Maximilian J, Lamprecht, Bernd, Dos Reis, Peo, Serodio da Rocha Baldotto, Clarissa, Venkova, Violetka, Bi, Minghong, Chen, Zhendong, Han, Zhigang, Hu, Yi, Li, Wei, Ma, Shenglin, Nan, Kejun, Shu, Yongqian, Wang, Kai, Yang, Nong, Zhang, Wei, Zhao, Jun, Zhao, Yanqiu, Zhou, Caicun, Zhou, Xiangdong, Skrickova, Jana, Hilgers, Werner, Moro-Sibilot, Denis, Bischoff, Helge, Lang, Susanne, Fülöp, Anea, Horváth, Zsolt, Laczó, Ibolya, Losonczy, György, Pápai Székely, Zsolt, Telekes, Anás, Bar, Jair, Gottfried, Maya, Heching, Norman Isaac, Bettini, Anna Cecilia, Minelli, Mauro, Roila, Fausto, Verderame, Francesco, Atagi, Shinji, Goto, Hisatsugu, Goto, Koichi, Hara, Yu, Hida, Toyoaki, Hotta, Katsuyuki, Kuyama, Shoichi, Morise, Masahiro, Nakahara, Yasuharu, Okamoto, Isamu, Shinoda, Masahiro, Umemura, Shigeki, Heniks, Lizza, Ungureanu, Anei, Luft, Alexander, Sakaeva, Dina, Smolin, Alexey, Statsenko, Galina, Vasilyev, Alexander, Vladimirova, Lyubov, Chovanec, Jozef, Urda, Michal, Ji, Jun Ho, Lee, Kyung Hee, Isla Casado, Dolores, Ponce Aix, Santiago, Hsia, Te-Chun, Wu, Shang-Yin, Çiçin, Irfan, Göksel, Tuncay, Özgüroğlu, Mustafa, Adamchuk, Hryhoriy, Bondarenko, Igor, Kryzhanivska, Anna, Shevnia, Serhii, Trukhin, Dmytro, Ursol, Grygorii, Voitko, Oleksandr, Vynnychenko, Ihor, Chen, Yuanbin, Chua, Winston, Dakhil, Shaker, Goldman, Jonathan W, Lakhanpal, Shailena, Powell, Steven, Stilwill, Joseph

“…Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has…”
Get full text

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial by Chen, Yuanbin, Reinmuth, Niels, Hotta, Katsuyuki, Özgüroğlu, Mustafa, Ji, Jun Ho, Garassino, Marina Chiara, Poltoratskiy, Artem, Ponce, Santiago, Bondarenko, Igor, Conev, Nikolay V, Armstrong, Jon, Byrne, Natalie, Jiang, Haiyi, Paz-Ares, Luis, Voitko, Nataliia, Poltoratskiy, Artem, Bondarenko, Igor, Chen, Yuanbin, Özgüroglu, Mustafa, Conev, Nikolay, Burghuber, Otto, Moiseenko, Vladimir, Reinmuth, Niels, Ursol, Grygorii, Pajkos, Gábor, Verderame, Francesco, Smolin, Alexey, Göksel, Tuncay, Dakhil, Shaker, Lee, Jong-Seok, Garcia Campelo, Maria Rosario, Alacacioglu, Ahmet, Casarini, Ignacio, Ilieva, Rumyana, Somfay, Attila, Roila, Fausto, Urda, Michal, Majem Tarruella, Margarita, Bettini, Anna Cecilia, Okamoto, Isamu, Mandziuk, Slawomir, Domine Gomez, Manuel, Wu, Shang-Yin, Knoble, Jeanna, Venkova, Violetka, Laack, Eckart, Bischoff, Helge, Fülöp, Andrea, Telekes, András, Kanda, Shintaro, Nakahara, Yasuharu, Lin, Sheng-Hao, Schaefer, Eric, Nikolinakos, Petros, Schneider, Jeffrey, Kultan, Juraj, Kolek, Vitezslav, Lee, Kyung Hee, Goloborodko, Olexandr, Kolesnik, Oleksii, Ostapenko, Yuriy, Stilwill, Joseph, De Marchi, Pedro Rafael Martins, Krasteva, Rositsa, Koubkova, Leona, Grohe, Christian, Heching, Norman Isaac, Harada, Daijiro, Nogami, Naoyuki, Nokihara, Hiroshi, Goto, Hisatsugu, Staal van den Brekel, Agnes, Ganea, Doina, Popova, Ekaterina, Sakaeva, Dina, Stresko, Marian, Demo, Pavol, Hsia, Te-Chun, Lee, Kang-Yun, Zarba, Juan Jose, Pastor, Andrea Viviana, Zukin, Mauro, Calabrich, Aknar, Dudov, Asen, Lang, Susanne, Kanazawa, Kenya, Hiltermann, Jeroen, Shparyk, Yaroslav, Kryzhanivska, Anna, Jamil, Rodney, Williamson, Michael, Han, Zhigang, Wang, Mengzhao, Li, Wei, Feng, Jifeng, Zhou, Xiangdong, Hu, Yi, Nan, Kejun, Zhang, Wei, Lin, Zhong

“…First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide) showed a significant improvement in overall survival versus…”
Get full text